首页> 美国卫生研究院文献>The Journal of Molecular Diagnostics : JMD >BIOMED-2 Multiplex Immunoglobulin/T-Cell Receptor Polymerase Chain Reaction Protocols Can Reliably Replace Southern Blot Analysis in Routine Clonality Diagnostics
【2h】

BIOMED-2 Multiplex Immunoglobulin/T-Cell Receptor Polymerase Chain Reaction Protocols Can Reliably Replace Southern Blot Analysis in Routine Clonality Diagnostics

机译:BIOMED-2多重免疫球蛋白/ T细胞受体聚合酶链反应协议可以可靠地取代常规印迹诊断中的Southern印迹分析

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

To establish the most sensitive and efficient strategy of clonality diagnostics via immunoglobulin and T-cell receptor gene rearrangement studies in suspected lymphoproliferative disorders, we evaluated 300 samples (from 218 patients) submitted consecutively for routine diagnostics. All samples were studied using the BIOMED-2 multiplex polymerase chain reaction (PCR) protocol. In 176 samples, Southern blot (SB) data were also available, and the two types of molecular results were compared. Results of PCR and SB analysis of both T-cell receptor and immunoglobulin loci were concordant in 85% of samples. For discordant results, PCR results were more consistent with the final diagnosis in 73% of samples. No false-negative results were obtained by PCR analysis. In contrast, SB analysis failed to detect clonality in a relatively high number of samples, mainly in cases of low tumor burden. We conclude that the novel BIOMED-2 multiplex PCR strategy is of great value in diagnosing patients with suspected B- and T-cell proliferations. Because of its higher speed, efficiency, and sensitivity, it can reliably replace SB analysis in clonality diagnostics in a routine laboratory setting. Just as with SB results, PCR results should always be interpreted in the context of clinical, immunophenotypical, and histopathological data.
机译:为了通过可疑的淋巴增生性疾病通过免疫球蛋白和T细胞受体基因重排研究建立最敏感,最有效的克隆诊断方法,我们评估了300份连续提交常规诊断的样本(来自218例患者)。所有样品均使用BIOMED-2多重聚合酶链反应(PCR)方案进行了研究。在176个样品中,还提供了Southern blot(SB)数据,并对两种类型的分子结果进行了比较。 T细胞受体和免疫球蛋白基因座的PCR和SB分析结果与85%的样本一致。对于不一致的结果,PCR结果与73%的样品的最终诊断结果更加一致。通过PCR分析未获得假阴性结果。相反,SB分析未能在相对大量的样品中检测到克隆性,主要是在低肿瘤负荷的情况下。我们得出结论,新颖的BIOMED-2多重PCR策略在诊断可疑B细胞和T细胞增殖的患者中具有重要价值。由于它具有较高的速度,效率和灵敏度,因此可以在常规实验室环境中可靠地取代SB分析,用于克隆诊断中。与SB结果一样,PCR结果应始终在临床,免疫表型和组织病理学数据的背景下进行解释。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号